US FDA approves AbbVie's drug for Parkinson's disease
US FDA approves AbbVie's drug for Parkinson's disease Sept 25 (Reuters) - The US Food and Drug Administration has approved AbbVie's ABBV.N drug for Parkinson's disease in adults, the health regulator's website showed on Friday.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96